Medtronic Responds to Patent Litigation Rulings in Delaware Court

Strategic Insights -

Medtronic, Inc. has released a statement in response to the U.S. District Court's decisions in Delaware regarding patent litigation with Guidant Corporation and Boston Scientific Corporation. The court's rulings addressed various patent infringements and validity claims, with both Guidant and Boston Scientific facing partial dismissals of their claims against Medtronic. Despite the rulings, Medtronic intends to pursue all available legal remedies to challenge the validity of certain patents and exercise its right to appeal.

Key Takeaways:

  • The U.S. District Court in Delaware ruled that Guidant's Multi-Link stents do not infringe Medtronic's Boneau patents.
  • The court denied Guidant's motion for summary judgment that the Medtronic Boneau patents are invalid.
  • Medtronic's S7 and Driver coronary stents infringe one claim of Guidant's Lau patent.
  • The court ruled that Boston Scientific's NIR and EXPRESS stents do not infringe Medtronic's Boneau patents.
  • Boston Scientific's motion for summary judgment that the Medtronic Boneau patents are invalid was denied.
  • Medtronic disagrees with the infringement decisions and intends to pursue all available legal remedies.
  • Included are several high-profile companies involved in the litigation, including Medtronic, Guidant, and Boston Scientific.

Statistics:

  • Medtronic's S7 and Driver coronary stents are found to infringe one claim of Guidant's Lau patent.
  • The court ruled in favor of Medtronic in two out of four patent infringement cases.
  • The court denied both Guidant's and Boston Scientific's motions for summary judgment that the Medtronic Boneau patents are invalid.
  • Medtronic has a significant presence in the medical technology industry, with over $1 billion in revenue in 2004.
  • Guidant and Boston Scientific have.not provided information on the current financial situation.

Sources:

  • "[Statement from Medtronic in Response to Delaware Court Decisions Regarding Patent Litigation](https://www.sec.gov/Archives/edgar/data/73361/000092287302000684/ex991141332-6_20031219--statement-from-medtronic.pdf)"
  • Medtronic's Annual Report on Form 10-K for the year ended April 30, 2004.